[1] [1] J. B. Gibbs, “Mechanism-Based Target Identification and Drug Discovery in Cancer Research,” Science, Vol. 287, No. 5466, 2000, pp. 1969-1973. http://dx.doi.org/10.1126/science.287.5460.1969
[2] C. Unger, “New Therapeutic Approaches in Cancer Treatment,” Drugs of the Future, Vol. 22, No. 12, 1997, pp. 1337-1345.
[3] P. Heffeter, M. A. Jacupec, W. Orner, S. Wild, N. G. Keyserlingk, L. Elbling, H. Zorbas, A. Korynevska, S. Knasmuller, H. Sutterluty, M. Micksche, B. K. Keppler and W. Berger, “Anticancer Activity of the Lanthanum Compound [Tris(1,10-phenanthroline) lanthanum(III)] tri thiocyanate (KP772; FFC24),” Biochemical Pharmacology, Vol. 71, No. 4, 2006, pp. 426-440. http://dx.doi.org/10.1016/j.bcp.2005.11.009
[4] J. Mann, A. Baron, Y. Opoku-Boahen, E. Johansson, G. Parkinson, L. R. Kelland and S. Neidle, “A New Class of Symmetric Bis-Benzimidazole-Based DNA Minor Groove Binding Agents,” Journal of Medicinal Chemistry, Vol. 44, No. 2, 2001, pp. 138-144. http://dx.doi.org/10.1021/jm000297b
[5] A. Seaton, C. Higgins, J. Mann, A. Baron, C. Bailly, S. Neidle and H. van den Berg, “Mechanistic and Anti-Proliferative Studies of Two Novel, Biologically Active Bis-Benzimidazoles,” European Journal of Cancer, Vol. 39, No. 17, 2003, pp. 2548-2555. http://dx.doi.org/10.1016/S0959-8049(03)00621-X
[6] Y.-H. Yang, M.-S. Cheng, Q.-H. Wang, H. Nie, N. Liao, J. Wang and H. Chen, “Design, Synthesis, and Anti-Tumor Evaluation of Novel Symmetrical Bis-Benzimida-zole,” European Journal of Medicinal Chemistry, Vol. 44, No. 17, 2009, pp. 1808-1812. http://dx.doi.org/10.1016/j.ejmech.2008.07.021
[7] H. A. Johnson and N. R. Thomas, “Polyhydroxylate-dazepanes as New Motifs for DNA Minor Groove Binding Agents,” Bioorganic & Medicinal Chemistry Letters, Vol. 12, No. 2, 2002, pp. 237-241. http://dx.doi.org/10.1016/S0960-894X(01)00719-3
[8] E. Rajanarendar, M. N. Reddy, S. R. Krishna, K. G. Reddy, Y. N. Reddy and M. V. Rajam, “Design, Synthesis, in Vitroantimicrobial And Anticancer Activity Of Novel Methylenebis-Isoxazolo[4,5-B]Azepines Derivatives,” European Journal of Medicinal Chemistry, Vol. 50, 2012, pp. 344-349. http://dx.doi.org/10.1016/j.ejmech.2012.02.013
[9] L. W. Deady, J. Desneves, A. J. Kaye, G. J. Finlay, B. C. Baguley and W. A. Denny, “Synthesis and Antitumor Activity of Some Indeno[1,2-b]Quinolone-Based Biscarboxamides,” Bioorganic & Medicinal Chemistry, Vol. 8, No. 5, 2000, pp. 977-984. http://dx.doi.org/10.1016/S0968-0896(00)00039-0
[10] R. Sánchez-Martín, J. M. Campos, A. Conejo-García, O. Cruz-López, M. Bánez-Coronel, A. Rodríguez-González, M. A. Gallo, J. C. Lacal and A. Espinosa, “Symmetrical Bis-Quinolinium Compounds: New Human Choline Kinase Inhibitors with Antiproliferative Activity against the HT-29 Cell Line,” European Journal of Medicinal Chemistry, Vol. 48, No. 9, 2005, pp. 3354-3363.
[11] S. Safe, S. Papineni and S. Chintharlapalli, “Cancer Chemotherapy with Indole-3-Carbinol, Bis(3’-Indolyl)-Methane and Synthetic Analogs,” Cancer Letters, Vol. 269, No. 2, 2008, pp. 326-338. http://dx.doi.org/10.1016/j.canlet.2008.04.021
[12] S. D. Cho, S. Chintharlapalli, M. Abdelrahim, S. Papineni, S. Liu, J. Guo, P. Lei, A. Abudayyeh and S. Safe, “5,5'-Dibromo-Bis(3'-Indolyl)Methane Induces Krüppel-Like Factor 4 and p21 in Colon Cancer Cells,” Molecular Cancer Therapeutics, Vol. 7, No. 7, 2008, pp. 2109-2120. http://dx.doi.org/10.1158/1535-7163.MCT-07-2311
[13] D. Bigg, S. Auvin, C. Lanco and G. Prevost, “Imidazolidine-2,4-Dione Derivatives and Use Thereof as a Medicament,” WO2010119194, 2010.
[14] G. Prevost, S. Auvin, C. Lanco, A. Liberatore and O. Lavergne, “Imidazolidine-2,4-Dione Derivatives, and Use Thereof as a Cancer Drugs,” EP 2 419 410, 2013.
[15] P. Y. Johnson and D. J. Kerkman, “The Chemistry of Hindered Systems. II. The Acyloin Reaction—An Approach to Regiospecifically Hydroxylated Tetramethy-lazacycloheptane Systems,” The Journal of Organic Chemistry, Vol. 41, No. 10, 1976, pp. 1768-1773. http://dx.doi.org/10.1021/jo00872a023
[16] P. Calabresi and J. Darnowski, “Use of Taurolidine to Treat Tumors,” US 6,429, 224, 2002.
[17] P. Calabresi, F. A. Goulette and J. W. Darnowski, “Taurolidine: Cytotoxic and Mechanistic Evaluation as a Novel Antineoplastic Agent,” Cancer Research, Vol. 61, No. 18, 2001, pp. 6816-6821.
[18] I. Perillo, E. Repetto, M. C. Caterina, R. Massa, G. Gut- kind and A. Salerno, “Synthesis, Spectroscopic and Bio- logical Properties of Bis(3-Arylimidazolidinyl-1)Methanes. A Novel Family of Antimicrobial Agents,” European Journal of Medicinal Chemistry, Vol. 40, No. 8, 2005, pp. 811-815. http://dx.doi.org/10.1016/j.ejmech.2005.03.010
[19] V. Sharma and M. S. Y. Khan, “Synthesis of Novel Tet- rahydroimidazole Derivatives and Studies for Their Bio- logical Properties,” European Journal of Medicinal Che- mistry, Vol. 36, No. 6, 2001, pp. 651-658. http://dx.doi.org/10.1016/S0223-5234(01)01256-9
[20] W. E. Craig and J. O. Van Hook, “Heterocyclic Ami- noalkil Imidazolidines and Hexahidropyrimidines,” US 2,675, 381, 1954.
[21] J. O. Van Hook and W. E. Craig, “N,N’-Bis(Aminoalkil) Derivatives of Imidazolines and Hexahidropyrimidines,” US 2,675, 387, 1954.
[22] M. C. Caterina, I. A. Perillo, L. Boiani, H. Pezaroglo, H. Cerecetto, M. Gonzalez and A. Salerno, “Imidazolidines as New Anti-Trypanosoma Cruzi Agents: Biological Evaluation and Structure-Activity Relationships,” Bioor- ganic & Medicinal Chemistry, Vol. 16, No. 5, 2008, pp. 2226-2234.
[23] M. C. Caterina, M. V. Corona, I. A. Perillo, A. Salerno, D. Benítez, H. Cerecetto and M. González, “Síntesis y Eva- luación in Vitro Frente a T. Cruzi de 1-Acil-3-Arilimi- dazolidinas,” 3er Workshop Argentino de Química Me- dicinal, Argentina, 2008, p. 47.
[24] G. S. de Carvalho, P. A. Machado, D. T. S. de Paula, E. S. Coimbra and A. D. da Silva, “Synthesis, Cytotoxicity, and Antileishmanial Activity of N,N'-Disubstitutede- thylenediamine and Imidazolidine Derivatives,” The Sci- entific World Journal, Vol. 10, 2010, pp. 1723-1728. http://dx.doi.org/10.1100/tsw.2010.176
[25] E. von Angerer, G. Kranzfelder, A. K. Taneja and H. Sch?nenberger, “N,N'-Dialkyl Bis(Dichorophenyl) Ethyl- enediamines and Imidazolidines: Relationship between Structure and Estradiol Receptor Affinity,” Journal of Medicinal Chemistry, Vol. 23, No. 12, 1980, pp. 1347- 1350. http://dx.doi.org/10.1021/jm00186a012
[26] E. von Angerer, G. Egginger, G. Kranzfelder, H. Bernhaus- er and H. Sch?nemberger, “N,N'-Dialkyl-1, 2-Bis(Hydro- xyphenyl) Ethylenediamines and N,N'-Dialkyl-4,5-Bis(4-Hy- droxyphenyl)Imidazolidines: Synthesis and Evaluation of Their Mammary Tumor Inhibitingactivity,” Journal of Medicinal Chemistry, Vol. 25, No. 7, 1982, pp. 832-837. http://dx.doi.org/10.1021/jm00349a013
[27] H. A. Nieper, “New Carcinostatic Compounds against Hela Cells,” ArztlForsch, Vol. 20, 1966, pp. 18-23.
[28] K. Sztanke, S. Fidecka, E. Kedzierska, Z. Karczmarzyk, K. Pihlaja and D. Matosiuk, “Antinociceptive Activity of New Imidazolidine Carbonyl Derivatives. Part 4. Synthe- sis and Pharmacological Activity of 8-Aryl-3,4-Dioxo- 2H,8H-6,7-Dihydroimidazo[2,1-c] [1,2,4]Triazines,” Euro- pean Journal of Medicinal Chemistry, Vol. 40, No. 2, 2005, pp. 127-134. http://dx.doi.org/10.1016/j.ejmech.2004.09.020
[29] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. Mc-Mahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, “New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,” Journal of the National Cancer Institute, Vol. 82, No. 13, 1990, pp. 1107-1112. http://dx.doi.org/10.1093/jnci/82.13.1107
[30] M. R. Grever, S. A. Schepartz and B. A. Chabner, “The National Cancer Institute: Cancer Drug Discovery and Development Program,” Seminars in Oncology, Vol. 19, No. 6, 1992, pp. 622-638.
[31] R. H. Shoemaker, “The NCI60 Human Tumour Cell Line Anticancer Drug Screen,” Nature Reviews Cancer, Vol. 6, No. 10, 2006, pp. 813-823. http://dx.doi.org/10.1038/nrc1951
[32] J. S. Driscoll, “The Preclinical New Drug Research,” Cancer Treatment. Reports, Vol. 68, No. 1, 1984, pp. 63- 67.
[33] I. Perillo, M. C. Caterina, J. Lopez and A. Salerno, “Syn- thesis of Substituted 1H-4,5-Dihydroimazolium Salt by Dehydrogenation of Imidazolidines,” Synthesis, No. 6, 2004, pp. 851-856.
[34] Y.-H. Liu, Q.-S. Liu and Z.-H. Zhang, “Amberlyst-15 as a New Andreusable Catalyst for Regioselective Ring- Opening Reactions of Epoxides to Alcoxy Alcohols,” Journal of Molecular Catalysis A: Chemical, Vol. 296, No. 1, 2008, pp. 42-46.
[35] L. D. Sasiambarrena, A. S. Cánepa and R. D. Bravo, “Synthesis of 1,2,4,5-Tetrahydro-3,2-Benzothiazepine 3,3-Dioxides Using Amberlyst-15,” Synthetic Communications, Vol. 41, No. 2, 2010, pp. 200-205. http://dx.doi.org/10.1080/00397910903533983
[36] R. Pal, T. Sarka and S. Khasnobis, “Amberlyst-15 in Organic Synthesis,” Arkivoc, Vol. 2012, No. 1, 2012, pp. 570-609. http://dx.doi.org/10.3998/ark.5550190.0013.114
[37] K. Singh, S. Sharma and A. Sharma, “Unique Versatility of Amberlyst 15. An Acid and Solvent-Free Paradigm towards Synthesis of Bis(Heterocyclyl)Methane Derivatives,” Journal of Molecular Catalysis A: Chemical, Vol. 347, No. 1, 2011, pp. 34-37. http://dx.doi.org/10.1016/j.molcata.2011.07.007